Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation

被引：19

作者：

Farinha, Jose Maria ^{[1
,2
]}

Jones, Ian D. ^{[1
,2
,3
]}

Lip, Gregory Y. H. ^{[1
,2
,4
]}

机构：

[1] Univ Liverpool, Liverpool John Moores Univ, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England

[2] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England

[3] Liverpool John Moores Univ, Sch Nursing & Allied Hlth, Liverpool, Merseyside, England

[4] Aalborg Univ, Dept Clin Med, Aalborg, Denmark

来源：

EUROPEAN HEART JOURNAL SUPPLEMENTS | 2022年 / 24卷

关键词：

Adherence; Atrial fibrillation; Integrated care; Integrated management; Non-vitamin K antagonist oral anticoagulants; Oral anticoagulation; Persistence; MOBILE HEALTH TECHNOLOGY; STROKE PREVENTION; ANTITHROMBOTIC THERAPY; DECISION-MAKING; MEDICINE RESIDENTS; EUROPEAN-SOCIETY; INTEGRATED CARE; BLEEDING RISK; WARFARIN; AF;

D O I：

10.1093/eurheartj/suab152

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Atrial fibrillation (AF) is associated with an increased risk of stroke, which can be prevented by the use of oral anticoagulation. Although non-vitamin K antagonist oral anticoagulants (NOACs) have become the first choice for stroke prevention in the majority of patients with non-valvular AF, adherence and persistence to these medications remain suboptimal, which may translate into poor health outcomes and increased healthcare costs. Factors influencing adherence and persistence have been suggested to be patient-related, physician-related, and healthcare system-related. In this review, we discuss factors influencing patient adherence and persistence to NOACs and possible problem solving strategies, especially involving an integrated care management, aiming for the improvement in patient outcomes and treatment satisfaction.

引用

页码：A42 / A55

页数：14

共 122 条

[1] Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review [J].